Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19

  • STATUS
    Recruiting
  • days left to enroll
    6
  • participants needed
    40
  • sponsor
    Canisius-Wilhelmina Hospital
Updated on 15 March 2021

Summary

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). While the majority of people recover after mild symptoms, a portion of COVID-19 patients develops respiratory failure. Coagulopathy and thromboembolism are prevalent in severe COVID-19, and these factors are associated with decreased survival. Coagulation is an intricate balance between clot promoting and dissolving processes in which vitamin K plays an essential role. Elastin is a major component of dynamic tissues such as lungs and arteries, and elastin calcification stimulates elastin degradation and vice versa. The vitamin K-dependent Matrix Gla Protein (MGP) protects elastin from both calcification and degradation.

Although technically feasible, direct quantification of blood vitamin K levels is not an appropriate method to assess overall vitamin K status due to differences in bioavailability and half-life time between the two naturally occurring vitamin K forms (vitamin K1 and K2). Measuring inactive levels of vitamin K-dependent proteins in the circulation is the method recommended by most experts, as it represents the systemic availability of both vitamin K1 and K2. Dp-uc (dephospho uncarboxylated, i.e. inactive) MGP and proteins induced by vitamin K absence (PIVKA-II) both inversely correlate with vitamin K status and can be used as surrogate markers of total vitamin K status.

Recently, we found a severely reduced vitamin K status (as quantified by dp-ucMGP) in COVID-19 patients compared to controls. In COVID-19 patients, low vitamin K status was also associated with poor outcome (defined as the need for invasive ventilation or death), accelerated elastin degradation (quantified by plasma (iso)desmosine (DES) a byproduct of elastin degradation). Based on these finding and previous studies, we hypothesize that improving vitamin K-status by vitamin K supplementation could have favorable effects on pulmonary damage and coagulopathy in COVID-19.

Description

The outbreak of coronavirus 2019 disease (COVID-19) has a major impact on health care worldwide. This infectious disease is caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). The majority of individuals who contract COVID-19 have mild symptoms, but a significant part develops respiratory failure due to severe pneumonia and/or acute respiratory distress syndrome (ARDS). The virus may also have extra pulmonary manifestations, including coagulopathy and venous thromboembolism, associated with decreased survival. The pathogenesis of this coagulopathy, and the links between pulmonary and thromboembolic manifestations of COVID-19 are incompletely understood. In KOVIT trial, the roll of vitamin K in the pathogenesis of these manifestations will be elucidated.

Vitamin K in coagulation and elastic fiber metabolism

Coagulation is an intricate balance between clot promoting and dissolving processes in which vitamin K plays an important role. Pro-coagulation factors II, VII, IX and X depend on vitamin K for carboxylation to fulfill their biological function. Besides this, vitamin K is also cofactor of anticoagulant protein C and protein S. A significant proportion of protein S is extrahepatically synthesized in endothelial cells, in contrast to the pro-coagulant factors and protein C. Protein S plays a local suppressive role against thrombosis.

Matrix Gla protein (MGP) is also vitamin K-dependent but not involved in intravascular coagulation. MGP has been generally studied as an inhibitor of vascular mineralization, and its role in the pulmonary compartment seems to be comparable. Besides preventing soft tissue calcification, it also protects against elastic fiber degradation. Elastic fibers are fundamental matrix components in lungs and have high calcium affinity. Degradation and mineralization of elastic fibers are related processes. Desphospho-uncarboxylated MGP (dp-ucMGP) i.e. inactive MGP is a robust biomarker of extrahepatic vitamin K status since it is inversely associated with vitamin K.

Insufficiency of vitamin K may develop within days of poor intake, particularly in pathological conditions of increased vitamin K utilization. During times of scarcity, micronutrients are reserved for use in processes that form the greatest threat to short-term survival. With regard to vitamin K insufficiency, it appears to be preferentially transported to the liver for the activation (via carboxylation) of procoagulant factors at the expense of extrahepatic vitamin K-dependent proteins such as MGP and protein S (figure 1).

Assessment of vitamin K status

In nature, vitamin K is found in food as vitamin K1 (phylloquinone) and vitamin K2 (menaquinones). Measuring circulating levels of these two forms of vitamin K is technically feasible but the value of such measurements is limited. Quantification of vitamin K-dependent proteins that have not been carboxylated yet, is a valuable method reflecting the functional deficit of vitamin K1 and K2. Determination of dp-ucMGP levels as well as the ratio between uncarboxylated and carboxylated osteocalcin are validated assays of extrahepatic vitamin K status.

Dp-ucMGP is a biomarker of extrahepatic vitamin K status. High dp-ucMGP reflects low vitamin K status and vice versa. Although increasing vitamin K consumption decreases the amount of dp-ucMGP. Circulating dp-ucMGP concentration can best be regarded as a reflection of the total extrahepatic vitamin K deficit, which refers to the amount of vitamin K that is needed to carboxylate all the uncarboxylated vitamin K-dependent proteins in the body. Hepatic vitamin K status is usually quantified by measuring levels of protein induced by vitamin K absence (PIVKA)-II (i.e. uncarboxylated prothrombin).

Rationale for study treatment

Recently, a reduced vitamin K status was found, as quantified by dp-ucMGP, in patients suffering from COVID-19 as compared to controls. In these patients, low vitamin K status was also associated with poor outcome (defined as the need for invasive ventilation or death) and accelerated elastic fiber degradation (quantified by plasma (iso)desmosine (DES) a byproduct of elastin degradation). In contrast, hepatic vitamin K status, measured by inactive factor II (also called protein-induced by vitamin K absence (PIVKA)-II) was unaffected in most patients (figure 2). Considering the preferential activation of hepatic over extrahepatic proteins.

In COVID-19, inflammation causes pulmonary elastic fiber damage, which could also lead to an upregulation of MGP and a draining of extrahepatic vitamin K. The significant correlation between increased dp-ucMGP levels, and elastic fiber degeneration and poor prognosis supports the theory that vitamin K insufficiency contributes to pulmonary pathology.

Hypothesis

It is hypothesized that improving vitamin K-status by vitamin K supplementation could have favorable effects on both pulmonary damage and coagulation abnormalities in COVID-19 patients.

Objective

The objective of the KOVIT trial is to evaluate the safety of oral vitamin K2 supplementation in patients suffering from COVID-19 requiring hospital admission.

Details
Condition COVID19
Treatment Placebo, Vitamin K2 in the form of Menaquinone-7 (MK-7)
Clinical Study IdentifierNCT04770740
SponsorCanisius-Wilhelmina Hospital
Last Modified on15 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

COVID-19 patients who are admitted to the CWZ with COVID-19, with a laboratory confirmed SARS-CoV-2 infection within the previous 96 hours
Respiratory failure requiring supplemental oxygen, defined as requiring supplemental oxygen to sustain an arterial PO2 70mmHg (measured by arterial blood gas) or an oxygen saturation of 94% (measured using a pulse oximeter)
At least 18 years old
Able to safely swallow the study medication or possibility of safely administering this through a nasogastric tube
Use of prophylactic heparin or LWMH according to hospital protocols, or use of therapeutic dosages if there is a medical indication for this
Informed consent signed by patient

Exclusion Criteria

Use of oral anticoagulation drugs; patients may be included when they have been switched to LMWH
Patients on vitamin K antagonists with a supra-therapeutic anticoagulation at admission who require vitamin K supplementation to correct this, or were administered vitamin K for this reason within the preceding 5 days
Patients already using vitamin K supplements at admission
Participation in another intervention study
Direct admission to an intensive care unit (ICU) for invasive ventilation at presentation
Confirmed active pulmonary embolism or deep venous thrombosis prior to inclusion
Known allergy to any of the components of the study medication or placebo
Patients who are hemodialysis dependent at admission
Pregnancy at the time of inclusion
Diagnosed malignancy at the time of inclusion
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note